NCT04768673View on ClinicalTrials.gov

A Study to Investigate the PK and Safety of CKD-393

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 26, 2021

Primary Completion Date

April 22, 2021

Study Completion Date

April 27, 2021

Conditions
Type II Diabetes
Interventions
DRUG

CKD-393 formulation I

single, oral administration of 2 tablets under fed condition

DRUG

CKD-393 formulation II

single, oral administration of 2 tablets under fed condition

DRUG

D501, D759, H053

single, oral administration of 1 D501, 1 D759 and 2 H053 under fed condition

Trial Locations (1)

03722

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT04768673 - A Study to Investigate the PK and Safety of CKD-393 | Biotech Hunter | Biotech Hunter